JP2021531756A5 - - Google Patents
Info
- Publication number
- JP2021531756A5 JP2021531756A5 JP2021500823A JP2021500823A JP2021531756A5 JP 2021531756 A5 JP2021531756 A5 JP 2021531756A5 JP 2021500823 A JP2021500823 A JP 2021500823A JP 2021500823 A JP2021500823 A JP 2021500823A JP 2021531756 A5 JP2021531756 A5 JP 2021531756A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- igg1
- domain monomer
- monomer
- polypeptide
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696746P | 2018-07-11 | 2018-07-11 | |
| US62/696,746 | 2018-07-11 | ||
| PCT/US2019/041324 WO2020014429A2 (en) | 2018-07-11 | 2019-07-11 | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531756A JP2021531756A (ja) | 2021-11-25 |
| JP2021531756A5 true JP2021531756A5 (https=) | 2022-07-20 |
| JPWO2020014429A5 JPWO2020014429A5 (https=) | 2022-07-20 |
Family
ID=69142497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500823A Withdrawn JP2021531756A (ja) | 2018-07-11 | 2019-07-11 | ＣＣＲ４を標的指向する改変Ｆｃ抗原結合ドメイン構築体に関する組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250346676A1 (https=) |
| EP (1) | EP3820517A4 (https=) |
| JP (1) | JP2021531756A (https=) |
| KR (1) | KR20210042324A (https=) |
| CN (1) | CN113164590A (https=) |
| AU (1) | AU2019302662A1 (https=) |
| BR (1) | BR112021000391A2 (https=) |
| CA (1) | CA3105985A1 (https=) |
| IL (1) | IL279987A (https=) |
| MX (1) | MX2021000290A (https=) |
| WO (1) | WO2020014429A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4463485A4 (en) * | 2022-01-12 | 2026-02-25 | Biomolecular Holdings Llc | Tetrahedral antibodies |
| US20250084169A1 (en) | 2022-01-12 | 2025-03-13 | Biomolecular Holdings Llc | Nk/monocyte engagers |
| WO2024221187A1 (en) * | 2023-04-24 | 2024-10-31 | Biomap Intelligence Technology Sg Pte.Ltd. | Heteromultimer polypeptides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6488930B1 (en) * | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| US20050287138A1 (en) * | 2003-10-08 | 2005-12-29 | Kyowa Hakko Kogyo Co., Ltd. | CCR4-specific antibody composition |
| US20090304715A1 (en) * | 2006-03-03 | 2009-12-10 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
| US8962806B2 (en) * | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| CA2766065C (en) * | 2009-06-30 | 2020-07-21 | Research Development Foundation | Immunoglobulin fc polypeptides |
| AU2013256010B2 (en) * | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| WO2017151971A2 (en) * | 2016-03-02 | 2017-09-08 | Momenta Pharmaceuticals, Inc. | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS |
| BR112018074056A2 (pt) * | 2016-05-23 | 2019-03-06 | Momenta Pharmaceuticals, Inc. | composições e métodos relacionados a construtos de fc manipulados |
-
2019
- 2019-07-11 BR BR112021000391-6A patent/BR112021000391A2/pt not_active IP Right Cessation
- 2019-07-11 AU AU2019302662A patent/AU2019302662A1/en not_active Abandoned
- 2019-07-11 KR KR1020217004244A patent/KR20210042324A/ko not_active Ceased
- 2019-07-11 CA CA3105985A patent/CA3105985A1/en active Pending
- 2019-07-11 EP EP19833821.2A patent/EP3820517A4/en not_active Withdrawn
- 2019-07-11 CN CN201980059453.2A patent/CN113164590A/zh active Pending
- 2019-07-11 MX MX2021000290A patent/MX2021000290A/es unknown
- 2019-07-11 WO PCT/US2019/041324 patent/WO2020014429A2/en not_active Ceased
- 2019-07-11 JP JP2021500823A patent/JP2021531756A/ja not_active Withdrawn
- 2019-07-11 US US17/259,061 patent/US20250346676A1/en active Pending
-
2021
- 2021-01-06 IL IL279987A patent/IL279987A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532085A5 (https=) | ||
| JP2021530498A5 (https=) | ||
| JP2018046872A5 (https=) | ||
| RU2019124709A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА | |
| JP2020514301A5 (https=) | ||
| JP2021531756A5 (https=) | ||
| JP2020018311A5 (https=) | ||
| JP2023022186A5 (https=) | ||
| JP2020184996A5 (https=) | ||
| Wu et al. | Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules | |
| JP2019059786A5 (https=) | ||
| RU2014100111A (ru) | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| HRP20201517T1 (hr) | Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123 | |
| RU2007139953A (ru) | Антитела к ccr5 и их применение | |
| JP2021530989A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| RU2013115927A (ru) | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ | |
| EP2135879A3 (en) | Ligand | |
| DE602006005200D1 (de) | Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften | |
| JP2009225799A5 (https=) | ||
| EP1864998A3 (en) | Binding molecules | |
| RU2011111640A (ru) | Антитела против cd5 | |
| JP2021531268A5 (https=) | ||
| JP2018527323A5 (https=) | ||
| JP2023129433A5 (https=) |